Journal of Psychopharmacology最新文献

{"title":"Genetic background and sex moderate the effects of adolescent nicotine exposure on adult functional neural circuits and behavior.","authors":"Hayreddin Said Ünsal, Carlos Novoa, Nanyin Zhang, Thomas J Gould","doi":"10.1177/02698811261464981","DOIUrl":"https://doi.org/10.1177/02698811261464981","url":null,"abstract":"<p><p>Adolescence is a critical neurodevelopmental stage marked by heightened plasticity and vulnerability to environmental influences such as nicotine. Nicotine disrupts neural function via nicotinic acetylcholine receptors, leading to long-term impairments in reward processing, cognition, and emotional regulation. While links between adolescent nicotine exposure and adult psychiatric or cognitive deficits are established, the influence of genetics and sex remains unclear. We examined the long-term effects of adolescent nicotine exposure on adult behavior and neural circuitry in male and female C57BL/6J and DBA/2J mice. Nicotine (24 mg/kg/day) or saline was administered via subcutaneous osmotic minipumps from postnatal day 37 for 12 days. Behavioral assessments 4 weeks later included the elevated plus maze for anxiety-related behavior and the open field test for locomotor activity after acute nicotine (0.81 mg/kg). Resting-state functional magnetic resonance imaging evaluated brain connectivity changes. Nicotine exposure altered both behavior and functional connectivity, depending on strain and sex. Adult female C57BL/6J mice exposed to nicotine during adolescence had lower anxiety-like behavior and higher locomotor activity, along with increased striatal-hippocampal connectivity, suggesting adaptations either directly related to nicotine exposure or compensatory adaptations. In contrast, adult female DBA/2J mice exposed to nicotine during adolescence showed widespread disruptions in cortico-striatal-thalamic, polymodal association, and hippocampal networks critical for cognitive and emotional regulation. Overall, greater effects were seen in female mice. Findings reveal that adolescent nicotine exposure drives enduring, strain- and sex-dependent changes in adult brain connectivity and behavior. Considering genetics and sex is essential for tailoring interventions for nicotine addiction and its neuropsychiatric consequences.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261464981"},"PeriodicalIF":5.3,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148579003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"No evidence for deleterious effects of psilocybin and MDMA on working memory or related neurophysiological activity in a non-clinical population: An uncontrolled exploratory study.","authors":"Neil Wayne Bailey, Samantha Lee Webb, Bernadette Mary Fitzgibbon, Nigel Christopher Denning, Traill Dowie, Monica Margaret Schweickle, Anish Modak, Grace Chan, Jackie Knight, Molly Waldron, Kirsten Gainsford, Hannah Hawkes, Sonia Zammit, Novi Christina Sutanto, Kate Godfrey, Paul Bernard Fitzgerald","doi":"10.1177/02698811261464991","DOIUrl":"https://doi.org/10.1177/02698811261464991","url":null,"abstract":"<p><strong>Background: </strong>Research indicates psychedelics hold therapeutic potential, but possible deleterious effects have been insufficiently examined. We explored working memory (WM) performance and WM-related neurophysiological activity before and after exposure to psilocybin or 3,4-methylenedioxymethamphetamine (MDMA) in an uncontrolled study.</p><p><strong>Methods: </strong>Healthy participants were exposed to a single dose of psilocybin or MDMA (data analysed from 29 participants for each drug, with 16 receiving both drugs after >3-month washout). One to 16 days before and 5-16 days after dosing, participants completed a 3back WM task and eyes-closed resting with electroencephalography (EEG), plus a 3back during a 3-month remote follow-up.</p><p><strong>Results: </strong>After dosing, both groups showed increased alpha to gamma WM-related oscillatory power (<i>p</i> < 0.001). After psilocybin, participants showed steeper WM-related aperiodic slopes (<i>p</i> = 0.018), an effect maximal in occipital electrodes (<i>p</i> < 0.001, Cohen's <i>d</i> = 0.802, BF₁₀ = 155.138), and significant in occipital electrodes during resting (<i>p</i> = 0.008). The MDMA group showed improved task accuracy in the post-dosing EEG session (<i>p</i> = 0.005, Cohen's <i>d</i> = 0.561, BF₁₀ = 7.809). Both groups showed improved accuracy at 3-months (<i>p</i>-holm < 0.001, Cohen's <i>d</i> = 0.678, BF₁₀ = 272.074).</p><p><strong>Conclusions: </strong>Our results are suggestive of enduring neurophysiological effects following a single dose of MDMA or psilocybin. Our results do not support concerns about cognitive impairments from single exposures to MDMA or psilocybin in controlled settings, suggesting clinical utility does not risk impairing WM. However, given the uncontrolled study design, future research is required to confirm our observations reflect drug-induced neurophysiological changes.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261464991"},"PeriodicalIF":5.3,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148578962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Silence is golden: Documenting the speech production of participants and support providers in psilocybin administration sessions for the treatment of post-traumatic stress disorder.","authors":"Robert F Dougherty, Nadav Liam Modlin, Niall M McGowan, Patrick Staples, Ella Williams, Patrick Clarke, Mario Shafiei, Carly Leininger, Merve Alti, Megan Croal, Lindsey Marwood, Namik Kirlić, Gregory A Ryslik, Guy M Goodwin","doi":"10.1177/02698811261464988","DOIUrl":"https://doi.org/10.1177/02698811261464988","url":null,"abstract":"<p><strong>Background: </strong>When administered alongside monitoring and support, psilocybin has shown promise in the treatment of multiple psychiatric conditions. However, the contribution and nature of participant support in the context of psychedelic trials are much debated.</p><p><strong>Aims: </strong>We sought to further illustrate the structure and format of the monitoring and support used in Compass Pathfinder Ltd (Compass) trials, with particular focus on the administration sessions.</p><p><strong>Methods: </strong>Audio recording transcripts from a 12-week clinical trial evaluating the efficacy of 25 mg COMP360 psilocybin in 22 participants with post-traumatic stress disorder were analyzed to measure speech rates (words-per-minute (WPM)) for participants and support providers. A thematic analysis was also conducted on post-dosing participant interviews to offer further insight into how monitoring and support were experienced by participants.</p><p><strong>Results: </strong>Comparison of support provider/participant WPM distinguished the administration from the preparation and follow-up sessions. Speech by either party during the administration sessions was rare; on average, 78% of the time was filled with silence, compared to 25% to 30% in non-administration sessions. Three main themes emerged in the thematic analysis: (1) support was minimally enacted, yet experientially salient, (2) autonomy was promoted through the introspective psychedelic state and non-directive support, and (3) primary modes of support during altered states of consciousness included reassurance and validation.</p><p><strong>Conclusions: </strong>The relative absence of verbal interaction suggests that the monitoring and support used in Compass administration sessions can be differentiated from practice in many conventional psychotherapies, 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy trials, and psycholytic treatment paradigms with psychedelic drugs.</p><p><strong>Clinicaltrials: </strong>gov Identifier:NCT05312151 (https://clinicaltrials.gov/study/NCT05312151).</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261464988"},"PeriodicalIF":5.3,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148471445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The increasing use of cognitive enhancing drugs by those with ADHD and neurotypical individuals: Societal demands, lifestyle preferences, and ethical issues.","authors":"Barbara J Sahakian, Christelle Langley","doi":"10.1177/02698811261466620","DOIUrl":"https://doi.org/10.1177/02698811261466620","url":null,"abstract":"<p><p>Attention deficit hyperactivity disorder (ADHD) is a highly heritable neurodevelopmental condition characterised by impairments in sustained attention, executive functioning, and emotional regulation, with significant lifelong consequences if untreated. Recent years have seen substantial increases in ADHD diagnoses and stimulant prescriptions across children, adolescents, and adults, alongside a parallel rise in the non-medical use of cognitive-enhancing drugs by neurotypical individuals. This review examines five key issues: factors driving rising ADHD diagnoses and prescriptions; the cognitive profile of ADHD and mechanisms of pharmacological treatments; reasons for increasing cognitive enhancer use in neurotypical populations; evidence for their efficacy in neurotypical individuals; and associated ethical implications. We review evidence implicating digital technology, parenting styles, educational incentives, and diagnostic practices in rising ADHD prevalence. Cognitive studies demonstrate that ADHD is associated with deficits in sustained attention, working memory, inhibitory control, and emotional regulation, underpinned by fronto-striatal dysfunction. Stimulant medications such as methylphenidate and lisdexamfetamine effectively improve 'cold' cognitive functions and change dysfuntional neural circuitry to a more typically developing pattern, though emotional dysregulation may persist. In neurotypical individuals, drugs such as methylphenidate and modafinil produce small-to-moderate improvements in cognition, particularly by increasing cognitive effort and motivation, with greatest benefits in those operating below optimal levels. However, their growing use raises ethical concerns regarding safety, fairness, coercion, and regulation. We argue that careful risk-benefit evaluation, long-term research studies, and informed policy are urgently needed to guide responsible use.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261466620"},"PeriodicalIF":5.3,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148447564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute behavioural effects of low-dose cannabidiol: A randomised crossover trial in healthy volunteers.","authors":"Lucy A Chester, François-Olivier Hebert, Pamela Lachance-Touchette, Amani Mahroug, Anita Abboud, Tess Pelletier McCrea, Samer Mansour, Stéphanie Marsan, Didier Jutras-Aswad","doi":"10.1177/02698811261464527","DOIUrl":"https://doi.org/10.1177/02698811261464527","url":null,"abstract":"<p><strong>Background: </strong>Cannabidiol (CBD) is widely consumed in low-dose products. However, evidence for its psychotropic effects at non-clinical doses is sparse and inconsistent.</p><p><strong>Aims: </strong>To characterise the acute behavioural effects of low-dose synthetic CBD in healthy volunteers. We hypothesised that 200 mg of CBD would produce a greater peak pleasant drug effect than a placebo.</p><p><strong>Methods: </strong>In a triple-blind, randomised, crossover trial at the CHUM research centre, Montreal, Canada, 70 healthy occasional cannabis users received single oral doses of 20, 50, 100 and 200 mg synthetic CBD and placebo immediately after a high-fat meal. The primary outcome, a participant-rated visual analogue scale of pleasant drug effect (0-100), was assessed at five timepoints post-dosing during each visit. Other measurements included additional participant ratings of drug effects, as well as positive and negative affect, dissociation, anxiety, blood pressure, heart rate, and respiratory rate.</p><p><strong>Results: </strong>Two hundred milligrams of synthetic CBD dose produced an average 12.8% [95% CI = 3.8% to 21.8%] higher peak pleasant drug effect score compared to placebo (Cohen's <i>d</i> = 0.479 [0.089 to 0.869], <i>p</i>_corr = 0.044). No other dose of CBD showed a significant effect for the primary outcome versus placebo. All adverse events were mild or moderate in severity.</p><p><strong>Conclusions: </strong>The highest dose of CBD tested produced a slight but perceptible pleasurable subjective drug effect. This effect may differ based on prandial state and in clinical populations and populations with heavier cannabis use. Single doses of 100 mg synthetic CBD or less are unlikely to produce any discernible psychoactive effect in healthy, occasional users.</p><p><strong>Clinical trial registration: </strong>The study was registered on ClinicalTrials.gov (NCT05407285).</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261464527"},"PeriodicalIF":5.3,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148447600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Caution in interpreting value-related change after psilocybin: Comment on Kerr-Gaffney et al. (2026).","authors":"Golnush Tahamtan, Olga Chernoloz","doi":"10.1177/02698811261466617","DOIUrl":"https://doi.org/10.1177/02698811261466617","url":null,"abstract":"","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261466617"},"PeriodicalIF":5.3,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148396497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mental resilience is not meaningfully associated with the frequency and severity of alcohol hangover.","authors":"Sanne E Schulz, Lydia E Devenney, Joris C Verster","doi":"10.1177/02698811261464990","DOIUrl":"https://doi.org/10.1177/02698811261464990","url":null,"abstract":"<p><p>Previous research presented mixed results on the relationship between mental resilience, that is, the ability to adapt to stress of major life events, and the frequency and severity of experiencing alcohol hangovers. An online survey among <i>n</i> = 854 UK and Irish adults who consume alcohol was conducted to investigate this relationship. Mental resilience was assessed with the Brief Resilience Scale (BRS) and the Connor-Davidson Resilience Scale (CD-RISC 2). No significant correlations were found between mental resilience and alcohol consumption outcomes. Correlations between mental resilience and hangover frequency and severity were small and not significant (all: |<i>r</i>| < -0.1). Multiple linear regression analyses showed that mental resilience was not a significant predictor of hangover severity (BRS: B = 0.039; 95% CI: -0.127, 0.205; <i>p</i> = 0.644, and CD-RISC 2: B = -0.008; 95% CI: -0.077, 0.092; <i>p</i> = 0.841) or hangover frequency (BRS: B = -0.078; 95% CI: -0.168, 0.012, <i>p</i> = 0.091, and CD-RISC 2: B = -0.043; 95% CI: -0.089, 0.003; <i>p</i> = 0.065).Together, these findings suggest that any association between mental resilience and alcohol hangover outcomes is likely to be small and of limited practical relevance.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261464990"},"PeriodicalIF":5.3,"publicationDate":"2026-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148387694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of antidepressants, anesthetics and sedatives/hypnotics on sleep-associated memory consolidation - A systematic review.","authors":"Janina Mischke, Kerstin Luedtke, Lisa Marshall","doi":"10.1177/02698811261456185","DOIUrl":"https://doi.org/10.1177/02698811261456185","url":null,"abstract":"<p><p>Considering the wide and increasing utilization of drugs which act upon the central nervous system, a pressing, infrequently investigated question is their potential impact on sleep-associated memory consolidation. Here the influence of approved pharmaceuticals on memory consolidation during sleep in healthy humans, rats, and mice was investigated. A systematic review of the literature was conducted according to PRISMA guidelines. Criteria to be met included healthy subjects, drug application after learning and a comparable placebo condition. Exclusion criteria included but were not limited to repetitive dosing and additional non-pharmacological interventions. A total of 65 studies were included, whereby a limited number of studies lent themselves to a meta-analysis. The risk-of-bias assessment showed a lack of reporting predominantly in animal studies. Meta-analysis was conducted for the influence of zolpidem on consolidation of the word-pair association task in human adults, which showed an improvement in memory consolidation (0.57 (95% confidence interval 0.04-1.10)). Most importantly, for memory consolidation, results point toward a favorable position of second-generation antidepressants compared to their first-generation counterparts. Knowledge of such cognitive effects in healthy subjects should encourage consideration in designing studies with patients and/or in patient care.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261456185"},"PeriodicalIF":5.3,"publicationDate":"2026-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148387771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ten practical suggestions for setting up a psychedelic study.","authors":"Alice Caulfield, Matthew Butler, Mitul A Mehta","doi":"10.1177/02698811261458350","DOIUrl":"10.1177/02698811261458350","url":null,"abstract":"<p><p>The therapeutic potential of psychedelics is currently being explored in a range of neuropsychiatric conditions. Nevertheless, their designation as Schedule 1 substances causes substantial regulatory and economic barriers to research. Rigorous human mechanistic studies are required to address the critical knowledge gaps surrounding the mechanisms underlying the putative treatment effects of psychedelics. This article presents practical guidance for navigating challenges relating to study design, legislation, and drug sourcing, to assist researchers in navigating the complex process of setting up human psychedelic studies, drawing on our experience of setting up non-clinical studies in the United Kingdom, while acknowledging that some of the content will be relevant for investigator-initiated studies more broadly.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"1010-1017"},"PeriodicalIF":5.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13376326/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148258284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurobiology and neuropharmacology of zebrafish social behavior.","authors":"Kirill V Apukhtin, Vyacheslav D Riga, Maria M Kotova, David S Galstyan, Longen Yang, Jiahao Cui, Lee Wei Lim, Murilo S de Abreu, Allan V Kalueff","doi":"10.1177/02698811251413496","DOIUrl":"10.1177/02698811251413496","url":null,"abstract":"<p><p>A popular model organism for studying neural and molecular mechanisms of behavior, the zebrafish (<i>Danio rerio</i>) displays a wide range of robust and quantifiable social phenotypes, including shoaling/schooling, social preference and learning, as well as aggression and mating behaviors. Zebrafish social behavior is influenced by various neurotransmitters and hormones (including serotonin, dopamine, isotocin, cortisol, and endocannabinoids) and can be modulated experimentally, including genetically and pharmacologically. Here, we summarize current knowledge on neurobiology and neuropharmacology of zebrafish social behavior, and discuss various effects of drugs and other manipulations that target this critical behavioral domain.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"1118-1148"},"PeriodicalIF":5.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146202026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}